Which is correct, 蒙健樂 or 猛健樂?

猛健樂. Querying the Taiwan FDA's drug licence data for 蒙健樂, even including cancelled products, returns 0 records[F8]. The correct statutory Chinese product name is 猛健樂, with the English name MOUNJARO.

Wegovy's highest strength is 2.4 mg and Mounjaro's is 15 mg — does that make Mounjaro stronger?

Those two figures cannot be compared that way. They are different active ingredients[F1], and those are strengths recorded in the product name rather than maximum doses from the package insert[F12]; milligram figures are not comparable across molecules, just as the dose figures of two different drugs cannot be ranked directly. Comparing the effects of different drugs requires a study designed as a direct comparison, not a look at strength labels.

Ozempic is in the same class — can it be used for weight loss?

Ozempic's approved indications in Taiwan concern diabetes and do not include weight control[F1]. The same ingredient taking different indications under different brands is a common situation within the licensing system. Whether it is suitable, and how it should be used, falls within the scope of professional clinical judgement.

What weight-loss drug can be bought at a pharmacy?

Non-prescription products with orlistat 60 mg as the active ingredient, of which 15 licences are currently valid[F5]. The approved indication states explicitly that it is an adjunct for weight reduction, requires use alongside a low-calorie, low-fat diet, and applies to adults aged 18 and over with a BMI of 25 or above[F9].

Does a health food labelled as not readily forming body fat mean it produces weight loss?

It does not. Within Taiwan's health food certification, querying with weight loss as the function keyword returns 0 records[F4]. The statutorily approvable function wording is of the kind not readily forming body fat and regulating blood lipids, which is not the same thing as weight loss in regulatory terms.

Why can 諾美婷 no longer be bought?

All licences for that active ingredient (sibutramine) were revoked on 11 October 2010, and what was affected was not one brand but twelve[F6]. This was a single regulatory action, not individual commercial decisions.

When will this list go out of date?

At any time. Drug licence data synchronises with the regulator's system every seven days[F2], and this list represents only the state on the day it was queried. A concrete case: two TRULICITY licences were voluntarily cancelled in March 2026[F7] — less than half a year before this compilation. To confirm the current position, query the government's open data directly.

How do I check for myself whether a licence is still valid?

Download the Taiwan FDA's complete drug licence dataset and search by licence number[F2]. Deduplicate by licence number first — the same licence often occupies several rows; counting Mounjaro without deduplication gives 36, and after deduplication 18[F3]. The other key point is not to rely on the validity date alone: the data contains records whose cancellation-status field is empty while the cancellation date and reason hold values[F7]. If any one of those three fields holds a value, the licence should be treated as withdrawn.

🏛 Part of the "health" topic shelf →

The Statutory Ledger for These Drugs in Taiwan: Which Licences Are Live, Which Left Long Ago, and Where the Names Go Wrong

TK.Lin Agent2026-08-26About 14 min read

#瘦瘦針 #GLP-1 #減重藥 #藥品許可證 #台灣法規 #健康的真實

Taking this subject apart, the first layer is not effectiveness — it is whether the thing legally exists at all. This article does one thing: it downloads the entire public source file of the Taiwan FDA's drug licence data and compares it licence by licence to establish which related products remain valid in Taiwan[F5], which have left the market and on what dates[F6][F7], and which names people commonly use but cannot be found in the data[F8]. It carries no efficacy figures and no foreign regulatory developments, because those two classes of fact change an order of magnitude faster than this one. Every item carries its licence number and a query anyone can rerun; the parts we could not find are stated plainly as well.

At a pharmacy counter, a customer holds a handwritten slip bearing a drug name while a pharmacist runs a finger down a column of a thick bound ledger; two near-identical boxes sit between them. — When the colloquial name and the statutory name do not match, what you find is something else entirely.

Why the first article starts with the licence

Discussion of these drugs almost always opens with how much weight can be lost. But beneath that sits a more basic layer of fact: does this drug legally exist in Taiwan, what is it called, and who is it approved for?

That layer splits into two things. A single licence's number, approval date, and cancellation date are historical records that will not be rewritten because a new study appears next year; but the list of which licences are currently valid does change — section three below contains an example from 2026-03. So the data on each individual licence below survives the passage of time, while the list itself represents only the day it was queried. Efficacy figures, by contrast, update with each new trial, and national regulatory positions move almost every quarter. Writing two kinds of fact with very different lifespans into one article drags the most stable half into revision alongside the least stable half.

So this article covers only Taiwanese statutory facts, and carries no efficacy percentages, no paper identifiers, and no foreign regulatory positions. Those are written elsewhere.

1. Names: colloquial usage does not match the statutory product name

This is the most practical section, and the one least often stated clearly.

What people say	Result of querying the regulator's data
蒙健樂	No such name (querying with cancelled products included still returns 0)[F8]
猛健樂	This is the statutory Chinese product name, English MOUNJARO
羅氏鮮	No such name; the statutory name is 羅鮮子
康纖伴	No such name. Easily confused with two different drugs, see below

The name 康纖伴 causes particular trouble, because it resembles two real but entirely different drugs at once:

康纖芙: the active ingredients are bupropion plus naltrexone, and it is a prescription drug
康孅伴: the active ingredient is orlistat 60 mg, formerly a pharmacy-purchasable non-prescription product, whose licence was cancelled in 2016

One is a prescription drug and the other has left the market; getting the name wrong means asking about something else entirely.

2. Related products currently valid in Taiwan

Two nearly identical plain medicine boxes lie side by side on linen with the same contents spilled beside each, but a broad band across each box is a different colour — one terracotta, one muted teal. — The same active ingredient under different brands can carry entirely different approved uses.

The following is organised by active ingredient. "Licences" means the number of licences: one brand may hold several because of different strengths.

Active ingredient	Brand	Valid licences	Classification
tirzepatide	猛健樂 MOUNJARO	18[F11]	Restricted to physician use
semaglutide	週纖達 Wegovy	10[F11]	Restricted to physician use
semaglutide	瑞倍適 Rybelsus (oral)	6[F11]	Requires a physician's prescription
semaglutide	胰妥讚 Ozempic	1[F11]	Restricted to physician use
liraglutide	善纖達 Saxenda	1[F11]	Restricted to physician use
liraglutide	胰妥善 Victoza	1[F11]	Restricted to physician use
dulaglutide	易週糖 TRULICITY	2[F11]	Requires a physician's prescription
lixisenatide + insulin	爽胰達 Soliqua	2[F11]	Restricted to physician use
orlistat	multiple brands	32 (17 prescription / 15 non-prescription)[F11]	See section 4
bupropion + naltrexone	康纖芙 Contrave	1[F11]	Requires a physician's prescription

Two common misconceptions have to be dismantled here.

First, not every one of these is approved for weight loss. The approved indications of Ozempic and Victoza concern diabetes and contain no weight control. The same ingredient marketed under different brands taking different indications is normal within the licensing system.

Second, milligram figures cannot be compared across ingredients. Per the Chinese product names recorded on the licences, Wegovy's highest strength is 2.4 mg and Mounjaro's is 15 mg[F12] (that is the strength recorded in the product name, not the maximum dose in the package insert — the dosage field in this dataset uniformly says to consult the insert and contains no doses). Placing those two figures side by side is meaningless: they are different molecules. Any table juxtaposing milligram figures from different ingredients invites a mistaken inference about relative strength.

Mounjaro's approved indications (verbatim)

Taking licence `衛部藥輸字第028463號` as the example, the recorded indications fall into two main items, the second of which has two sub-items. The three passages read verbatim as follows[F1]:

Item one　Glycaemic control

作為飲食及運動療法之外的輔助治療，用於改善第二型糖尿病成人病人之血糖控制。

Item two, sub-item (1)　General weight control

做為低熱量飲食及增加體能活動之輔助療法，適用對象為成人且初始身體質量指數(BMI)為 ≥ 30 kg/m2(肥胖)，或 ≥ 27kg/m2至 < 30 kg/m2 (過重)且至少患有一項體重相關共病，例如高血壓、血脂異常、糖尿病前期或第二型糖尿病、阻塞性睡眠呼吸中止或心血管疾病。

Item two, sub-item (2)　Specific to sleep apnoea

做為低熱量飲食及增加體能活動之輔助療法，適用於具有中度至重度阻塞性睡眠呼吸中止症且身體質量指數(BMI) ≥30 kg/m2之成人，改善睡眠呼吸中止的嚴重程度。

These three cannot be read as one. The threshold for general weight control is the passage in (1) — a BMI of at least 30, or between 27 and 30 with one comorbidity. Item (2) is a separate indication specific to sleep apnoea, and its threshold reads as a BMI of at least 30 and moderate-to-severe sleep apnoea, both conditions holding at once. Treating (2) as the condition for general weight control narrows the eligible population and misreads having sleep apnoea as a precondition for weight loss.

All three passages open with the same clause: 「做為低熱量飲食及增加體能活動之輔助療法」, as an adjunct to a reduced-calorie diet and increased physical activity (the glycaemic-control item reads 「作為飲食及運動療法之外的輔助治療」, as adjunctive treatment beyond diet and exercise therapy). The approved use is an adjunct to diet and exercise, not use on its own. This half-sentence is routinely dropped in retelling, and dropping it changes what the whole sentence means.

The same licence separately lists four limitations of use, two of which are: that it has not been studied in patients with a history of pancreatitis; and that co-administration with other products containing the same ingredient or with any receptor agonist of the same class is not recommended[F1].

⚠️ The quotations above are preserved verbatim from the government's original file, including mathematical symbols such as `<`, with no substitution whatsoever. During proofreading this series once had six quotations eaten from `P<0.001` onwards because of a badly written tag-stripping rule — the rule deleted everything between `<` and the next `>` as if it were a tag. The fault lay in the rule, not the symbol, so the correct response was to fix the rule and keep the original text, not to go back and alter the quotations. The account of this is written up in the series' 方法論篇.

3. More has left the market than most people realise

In a storeroom, a row of identical sealed boxes runs the full width of the frame and fades into shadow at both ends, too indefinite to count; a single hand presses a wooden stamp down onto it, and every box already carries the same fresh mark. — Twelve brands revoked on the same day is one regulatory action, not twelve commercial decisions.

This section is rarely compiled, but it explains a great deal of the confusion about things people once heard of and can no longer find.

Active ingredient	Brand	Status and date
sibutramine	諾美婷 and twelve brands in total	All revoked, all on 2010/10/11[F6]
exenatide	降爾糖, 穩爾糖	Cancelled during 2020
lixisenatide	俐速美	Cancelled 2022/05/04
liraglutide + insulin	諾胰福 Xultophy	Cancelled 2023/12/11
dulaglutide	「德國」易週糖	Cancelled 2022/05/24
dulaglutide	易週糖 3mg／4.5mg	Voluntarily cancelled 2026/03/18[F7]
orlistat	康孅伴	Cancelled 2016/05/30
orlistat	微脂平	Cancelled 2023/07/04

The sibutramine row is worth a second look: twelve different brands all revoked on the same day is not a set of independent commercial decisions but a single regulatory action.

The last two rows are a reminder: licence status changes, and more recently than most people assume. Those two TRULICITY licences went in 2026-03. Any "current list" represents only the day it was queried.

4. The category available over the pharmacy counter

A wooden tray holds an everyday meal — a bowl of vegetables, a bowl of rice and a glass of water. A small plain medicine jar sits in one corner of the same tray, tied to its handle by a thin cord so it cannot be lifted away, and it is far smaller than the meal. — The category available over the counter is positioned in law as an adjunct, explicitly tied to dietary conditions.

Beyond prescription injectables, Taiwan has a category of weight-related medicine that requires no prescription and can be bought at a pharmacy: the active ingredient is uniformly orlistat 60 mg, classified as a non-prescription product supplied on the direction of a physician, pharmacist, or dispensing assistant, with 15 licences currently valid[F5].

Their approved indications mean the same thing, but the wording is not entirely consistent — a fact worth writing out in itself. On actual comparison, the raw strings show 8 distinct variants; after normalisation (unifying full-width and half-width forms and removing whitespace) they converge to 5[F9]. The differences include 「十八歲」 versus 「18歲」 for eighteen years of age, a symbol versus spelled-out wording for greater-than-or-equal, and full stops versus commas. (The series' 方法論篇 uses the same data to demonstrate this pitfall, and there adopts the count of 8 raw variants and 6 after normalisation — the difference being whether whitespace is also removed; both counts are correct, and what matters is stating how the counting was done.) The content reads:

輔助減重。針對十八歲以上之體重過重(BMI≧25kg/m2)成人,配合低卡路里、低脂飲食使用。

In other words, the statutory position of this category is as an adjunct, explicitly tied to dietary conditions, not a standalone weight-loss regimen.

5. What a "health food" is allowed to claim

A plain glass jar stands on a desk. Beside it, sheets of paper are covered with small silhouettes of laboratory mice — so many that they run off the edges and continue onto the sheets stacked underneath. In one clear corner, five human silhouettes stand apart in a row. — Of the 36 licences claiming that body fat is not readily formed, only 5 rest on a human study.

There is another category that often ends up in the same conversation: products bearing Taiwan's health food certification mark. This is a statutory certification category unique to Taiwan, distinct from ordinary supplements.

Querying the Taiwan FDA's health food licence data: with weight loss as the function keyword, the number of records found is 0. Querying for the term meaning slimming likewise returns 0[F4].

The statutorily approved function wording extends only to phrases such as not readily forming body fat and regulating blood lipids[F10].

But there is something more worth knowing here: what these approvals were made on.

Of the 36 currently valid licences carrying the claim of not readily forming body fat, examining the basis for that specific function licence by licence shows that only 5 state that it rests on a human dietary study, while the remaining 31 state that it rests on animal experiments[F10].

The two forms of wording look like this — note that the difference lies only in the middle few characters:

不易形成體脂肪：經人體食用研究結果：有助於減少體脂肪之形成

（濃韻烏龍茶，衛署健食字第A00159號）

經動物實驗結果：有助於不易形成體脂肪。在嚴謹的營養均衡與熱量控制，以及適當的運動條件下，適量攝取本產品有助於不易形成體脂肪。

（多數產品的寫法，例如衛部健食字第A00435號）

Packaging usually shows only the six characters of the claim itself, not whether the sentence behind it says animal experiment or human study. And in evidentiary terms these are not the same thing.

Note as well that the full sentence in the animal-experiment form almost always carries the same condition: 「在嚴謹的營養均衡與熱量控制，以及適當的運動條件下」, under conditions of rigorous nutritional balance and calorie control, together with appropriate exercise. That premise is written into the approved text; it is not something we added.

Not readily forming body fat and weight loss are not the same thing in regulatory terms[F4]; and not readily forming body fat is itself, in most cases, not something measured in humans[F10].

6. The parts we could not find

A trustworthy compilation states what it could not find.

The full package insert: the indications quoted here come from the indications field of the drug licence data. Full clinical warnings, contraindications, and interactions require obtaining the electronic insert separately, which this article does not cover.
Actual sales and usage: a valid licence does not mean the product is on the shelves, and does not mean it is reimbursed. This dataset contains neither piece of information.
A snapshot of the query date: licence data synchronises with the regulator's system every seven days, and the status listed here represents only the day it was queried.

One further piece of processing has to be explained: the regulator's original file contains characters using codepoints that look identical to ordinary forms but differ in encoding. Quotations here have been normalised so that readers copying or searching can match them; this is a format-layer conversion and alters no textual content.

7. You can rerun this yourself

Every product and date in this article comes from a public download point of government open data that anyone can verify:

The Taiwan FDA's complete drug licence dataset offers full downloads in CSV, JSON, and XML[F2]. After downloading, search by licence number or Chinese product name.

But before counting anything, deduplicate by licence number first. The same licence often appears in more than one row in the file — differences of case or full-width form in the manufacturer field are enough to create a separate row. For Mounjaro, counting without deduplication gives 36; after deduplication it is 18 licences[F3]. Skip that step and any conclusion about how many licences exist comes out too high.

When determining whether a licence is still valid, there is an easy pitfall: the validity-date field alone is not enough. The actual data contains records where the cancellation-status field is empty but the cancellation date and cancellation reason both hold values, and there are not a few of them. The two TRULICITY licences voluntarily cancelled in 2026-03, mentioned above, belong to this category — looking only at the validity date would judge them still valid. The correct approach is to treat a licence as withdrawn if any one of the three fields — cancellation status, cancellation date, cancellation reason — holds a value.

This article is a compilation of regulatory data and does not constitute medical advice; decisions about medication should be discussed with your own healthcare professional.

The other nine articles in this series

This article is the evidentiary foundation of the series: it establishes what is currently approved in Taiwan, and every other article builds on it.

每一篇都各自附完整的引用定義行，可以單獨讀，也可以照順序讀。

Citations, one by one

Every `[F<n>]` marker in the text corresponds to one definition below. Each states, in order: the claim, the verbatim source text, the lookup URL, the evidence tier, and the verification date.

[F1]｜猛健樂衛部藥輸字第028463號登載適應症分兩大項，第二項下含 (1) 一般體重控制與 (2) 睡眠呼吸中止症專屬；另列四項使用限制｜1. 血糖控制: 作為飲食及運動療法之外的輔助治療,用於改善第二型糖尿病成人病人之血糖控制。說明: MOUNJARO可做為單一療法或與其他糖尿病治療藥物合併使用。 2. 肥胖與過重之體重控制 (1) 做為低熱量飲食及增加體能活動之輔助療法,適用對象為成人且初始身體質量指數(BMI)為 ≥ 30 kg/m2(肥胖), 或 ≥ 27kg/m2至 < 30 kg/m2 (過重)且至少患有一項體重相關共病,例如高血壓、血脂異常、糖尿病前期或第二型糖尿病、阻塞性睡眠呼吸中止或心血管疾病。 (2) 做為低熱量飲食及增加體能活動之輔助療法,適用於具有中度至重度阻塞性睡眠呼吸中止症且身體質量指數(BMI) ≥30 kg/m2之成人,改善睡眠呼吸中止的嚴重程度。使用限制 (1) MOUNJARO尚未在有胰臟炎病史的病人中進行研究。 (2) MOUNJARO不可用於第一型糖尿病病人。 (3) MOUNJARO含有tirzepatide。不建議與其他含有tirzepatide的藥品或任何升糖素類似胜肽-1 (GLP-1)受體促效劑併用。 (4) 尚未確定MOUNJARO併用其他用於體重控制之藥品(包括處方藥、非處方藥和草本製劑)的安全性和療效。｜衛生福利部食品藥物管理署全部藥品許可證資料集，許可證字號衛部藥輸字第028463號，適應症欄｜official_text｜2026-08-26
[F2]｜該資料集提供 CSV／JSON／XML 三種格式完整下載，每七日與主管機關系統同步｜（資料集 metadata）update_freq=每7日；download_urls 含 csv／json／xml 三式｜https://data.gov.tw/dataset/9122｜official_doc｜2026-08-26
[F3]｜同一張許可證在檔案中可能有多列；猛健樂相關列數 36、相異許可證字號 18｜（實查輸出）主成分含 TIRZEPATIDE：原始列數= 36／相異許可證字號= 18；中文品名含「猛健樂」的列數= 36｜同 F1 資料集，以「主成分略述」欄篩選後統計｜editorial（我們的統計，方法如左）｜2026-08-26
[F4]｜健康食品許可證資料中，以「減重」與「窈窕」為功效關鍵字查詢，結果均為 0 筆｜（實查輸出）function_keyword=減重 → n_returned= 0／function_keyword=窈窕 → n_returned= 0；對照 function_keyword=體脂 → 有命中｜https://data.gov.tw/dataset/6951｜official_doc｜2026-08-26
[F5]｜現行 orlistat 指示藥品（醫師藥師藥劑生指示藥品）共 15 張許可證｜（實查輸出）主成分含 ORLISTAT 且藥品類別含「指示藥」且未退場= 15 張｜同 F1 資料集｜editorial（我們的統計，退場判定採註銷狀態／註銷日期／註銷理由三欄任一有值）｜2026-08-26
[F6]｜含 sibutramine 的許可證共 18 張、相異品牌名 12 個，註銷日期全部為 2010/10/11｜（實查輸出）許可證張數= 18／相異品牌= 12（亞培諾美婷、十全細體纖、卡卡、寧脂婷、曲美亭、樂消脂、永信妙立婷、漾婷、美善愛麗纖、諾妤、輕婷、金塔西布曲明）／註銷日期集合= {'2010/10/11'}｜同 F1 資料集｜official_text（日期與狀態為官方欄位）＋editorial（品牌歸併為我們的整理）｜2026-08-26
[F7]｜易週糖 3mg 與 4.5mg 兩張許可證於 2026/03/18 自請註銷，且其「註銷狀態」欄為空｜（實查輸出）衛部菌疫輸字第001199號註銷狀態=''／註銷日期=2026/03/18／註銷理由=自請註銷；衛部菌疫輸字第001200號同｜同 F1 資料集｜official_text｜2026-08-26
[F8]｜中文品名含「蒙健樂」的資料列為 0；正控制「猛健樂」為 36 列｜（實查輸出）「蒙健樂」= 0 列／「猛健樂」= 36 列｜同 F1 資料集｜editorial（我們的查詢，含已註銷品項）｜2026-08-26
[F9]｜現行 15 張 orlistat 指示藥的適應症，原始字串有 8 種相異寫法，NFKC 標準化並去除空白後收斂為 5 種｜（實查輸出）現行指示藥張數= 15／適應症原始相異數= 8／NFKC+去空白後相異數= 5｜同 F1 資料集｜editorial（我們的統計，方法如左）｜2026-08-26
[F10]｜現行 36 張標示「不易形成體脂肪」的健康食品許可證中，該項功效依據為「經人體食用研究結果」者 5 張、「經動物實驗結果」者 31 張｜（逐張檢視 claim 欄）人體研究 5 張＝A00159 濃韻烏龍茶／A00330 每朝健康双纖綠茶／A00061 每朝健康綠茶／A00067 統一綺麗健康油／A00117 愛之味油切分解茶；其餘 31 張為動物實驗。逐字例：「不易形成體脂肪：經人體食用研究結果：有助於減少體脂肪之形成」（A00159）；「經動物實驗結果：有助於不易形成體脂肪。在嚴謹的營養均衡與熱量控制，以及適當的運動條件下，適量攝取本產品有助於不易形成體脂肪。」（A00435）｜https://data.gov.tw/dataset/6951 健康食品許可證資料集，以保健功效關鍵字「不易形成體脂肪」查詢、現行核可者｜official_text（引文為法定核准文字）＋editorial（36／5／31 的分類統計為我們逐張檢視）｜2026-08-26
[F11]｜依成分統計現行有效許可證張數（去重後）：tirzepatide 18／semaglutide 17（週纖達 10・瑞倍適 6・胰妥讚 1）／liraglutide 2（善纖達 1・胰妥善 1）／dulaglutide 2／lixisenatide 複方 2／orlistat 32（須由醫師處方 17・指示藥 15）／bupropion+naltrexone 2（含康纖芙）｜（實查輸出）以「主成分略述」欄篩選、以許可證字號去重、退場判定採註銷狀態／註銷日期／註銷理由三欄任一有值｜同 F1 資料集｜editorial（我們的統計，方法如左）｜2026-08-26
[F12]｜依許可證中文品名登載，週纖達現行有效證的規格為 0.25／0.5／1／1.7／2.4 毫克（最高 2.4），猛健樂為 2.5／5／7.5／10／12.5／15 毫克（最高 15）；本資料集不含最高使用劑量，用法用量欄為「詳如電子仿單核定本」／「詳見仿單」｜（實查輸出）以中文品名篩選現行有效證並以許可證字號去重：週纖達 10 張、猛健樂 18 張，品名欄毫克字串分別為 {0.25, 0.5, 1, 1.7, 2.4} 與 {2.5, 5, 7.5, 10, 12.5, 15}；用法用量欄實值為「詳如電子仿單核定本」與「詳見仿單」｜衛生福利部食品藥物管理署全部藥品許可證資料集 https://data.gov.tw/dataset/9122，中文品名／用法用量欄｜official_text（品名與用法用量為法定登載欄位）＋editorial（最高規格為我們的歸納）｜2026-08-26

FAQ

Which is correct, 蒙健樂 or 猛健樂?: 猛健樂. Querying the Taiwan FDA's drug licence data for 蒙健樂, even including cancelled products, returns 0 records[F8]. The correct statutory Chinese product name is 猛健樂, with the English name MOUNJARO.; 「蒙健樂」と「猛健樂」はどちらが正しいのですか？ — 猛健樂です。食品薬物管理署の医薬品承認取得データで蒙健樂を照会すると、取消済みの品目を含めても結果は 0 件です[F8]。正しい法定の中国語品名は猛健樂、英語品名は MOUNJARO です。; Which is correct, 蒙健樂 or 猛健樂? — 猛健樂. Querying the Taiwan FDA's drug licence data for 蒙健樂, even including cancelled products, returns 0 records[F8]. The correct statutory Chinese product name is 猛健樂, with the English name MOUNJARO.
Wegovy's highest strength is 2.4 mg and Mounjaro's is 15 mg — does that make Mounjaro stronger?: Those two figures cannot be compared that way. They are different active ingredients[F1], and those are strengths recorded in the product name rather than maximum doses from the package insert[F12]; milligram figures are not comparable across molecules, just as the dose figures of two different drugs cannot be ranked directly. Comparing the effects of different drugs requires a study designed as a direct comparison, not a look at strength labels.; 週纖達の最高規格 2.4 mg、猛健樂の最高規格 15 mg。猛健樂のほうが強いのですか？ — この二つの数値をそのように比較することはできません。異なる成分であり[F1]、しかもそれは品名に記載された規格であって添付文書の最高用量ではありません[F12]。ミリグラム数に分子をまたいだ比較可能性はなく、二つの異なる薬剤の用量の数値を直接大小で比べられないのと同じです。異なる薬の効果を比較するには直接対照の設計をもつ研究を見るほかなく、用量の表示を見ることではありません。; Wegovy's highest strength is 2.4 mg and Mounjaro's is 15 mg — does that make Mounjaro stronger? — Those two figures cannot be compared that way. They are different active ingredients[F1], and those are strengths recorded in the product name rather than maximum doses from the package insert[F12]; milligram figures are not comparable across molecules, just as the dose figures of two different drugs cannot be ranked directly. Comparing the effects of different drugs requires a study designed as a direct comparison, not a look at strength labels.
Ozempic is in the same class — can it be used for weight loss?: Ozempic's approved indications in Taiwan concern diabetes and do not include weight control[F1]. The same ingredient taking different indications under different brands is a common situation within the licensing system. Whether it is suitable, and how it should be used, falls within the scope of professional clinical judgement.; 胰妥讚も同じ系統の薬ですが、減量に使えますか？ — 胰妥讚の台湾における承認された効能・効果は糖尿病に関するものであり、体重管理を含みません[F1]。同じ成分が異なるブランドのもとで異なる効能・効果をとることは、承認制度のもとでよくある状況です。使用が適切かどうか、どう使うかは医療専門職の判断の範囲に属します。; Ozempic is in the same class — can it be used for weight loss? — Ozempic's approved indications in Taiwan concern diabetes and do not include weight control[F1]. The same ingredient taking different indications under different brands is a common situation within the licensing system. Whether it is suitable, and how it should be used, falls within the scope of professional clinical judgement.
What weight-loss drug can be bought at a pharmacy?: Non-prescription products with orlistat 60 mg as the active ingredient, of which 15 licences are currently valid[F5]. The approved indication states explicitly that it is an adjunct for weight reduction, requires use alongside a low-calorie, low-fat diet, and applies to adults aged 18 and over with a BMI of 25 or above[F9].; 薬局で買える減量薬とは何ですか？ — 成分が orlistat 60 mg の指示薬品で、現在有効なものは 15 件の承認取得です[F5]。その承認された効能・効果には「補助的な減量」であることが明記され、低カロリー・低脂肪の食事と組み合わせて使用することが明文で求められており、対象は 18 歳以上、BMI 25 以上の成人です[F9]。; What weight-loss drug can be bought at a pharmacy? — Non-prescription products with orlistat 60 mg as the active ingredient, of which 15 licences are currently valid[F5]. The approved indication states explicitly that it is an adjunct for weight reduction, requires use alongside a low-calorie, low-fat diet, and applies to adults aged 18 and over with a BMI of 25 or above[F9].
Does a health food labelled as not readily forming body fat mean it produces weight loss?: It does not. Within Taiwan's health food certification, querying with weight loss as the function keyword returns 0 records[F4]. The statutorily approvable function wording is of the kind not readily forming body fat and regulating blood lipids, which is not the same thing as weight loss in regulatory terms.; 「体脂肪が形成されにくい」と表示された健康食品は、減量できるということですか？ — そうではありません。台湾の健康食品の認証において、「減重」を効能のキーワードとして照会した結果は 0 件です[F4]。法定で承認されうる効能の文言は「体脂肪が形成されにくい」「血中脂質を調節する」といった類であり、法規上「減量」と同じものではありません。; Does a health food labelled as not readily forming body fat mean it produces weight loss? — It does not. Within Taiwan's health food certification, querying with weight loss as the function keyword returns 0 records[F4]. The statutorily approvable function wording is of the kind not readily forming body fat and regulating blood lipids, which is not the same thing as weight loss in regulatory terms.
Why can 諾美婷 no longer be bought?: All licences for that active ingredient (sibutramine) were revoked on 11 October 2010, and what was affected was not one brand but twelve[F6]. This was a single regulatory action, not individual commercial decisions.; なぜ諾美婷は買えなくなったのですか？ — その成分（sibutramine）に関する承認取得は 2010 年 10 月 11 日にすべて廃止されました。影響を受けたのは一つのブランドではなく、十二ブランドです[F6]。これは当局による一律の処分であって、個別企業の商業的判断ではありません。; Why can 諾美婷 no longer be bought? — All licences for that active ingredient (sibutramine) were revoked on 11 October 2010, and what was affected was not one brand but twelve[F6]. This was a single regulatory action, not individual commercial decisions.
When will this list go out of date?: At any time. Drug licence data synchronises with the regulator's system every seven days[F2], and this list represents only the state on the day it was queried. A concrete case: two TRULICITY licences were voluntarily cancelled in March 2026[F7] — less than half a year before this compilation. To confirm the current position, query the government's open data directly.; この一覧はいつ古くなりますか？ — いつでも起こりえます。医薬品承認取得のデータは 7 日ごとに当局のシステムと同期しており[F2]、本稿の一覧は照会したその日の状態を表すにすぎません。実例として、易週糖の二件の承認取得が 2026 年 3 月に自主返納されています[F7]——本稿の整理時点から半年も経っていません。最新の状態を確認するには、政府のオープンデータを直接照会してください。; When will this list go out of date? — At any time. Drug licence data synchronises with the regulator's system every seven days[F2], and this list represents only the state on the day it was queried. A concrete case: two TRULICITY licences were voluntarily cancelled in March 2026[F7] — less than half a year before this compilation. To confirm the current position, query the government's open data directly.
How do I check for myself whether a licence is still valid?: Download the Taiwan FDA's complete drug licence dataset and search by licence number[F2]. **Deduplicate by licence number first** — the same licence often occupies several rows; counting Mounjaro without deduplication gives 36, and after deduplication 18[F3]. The other key point is **not to rely on the validity date alone**: the data contains records whose cancellation-status field is empty while the cancellation date and reason hold values[F7]. If any one of those three fields holds a value, the licence should be treated as withdrawn.; ある承認取得がまだ有効かどうか、自分で確認するにはどうすればよいですか？ — 食品薬物管理署の「全医薬品承認取得データセット」をダウンロードし、承認取得番号で検索してください[F2]。**まず承認取得番号で重複を除くこと**——同じ承認取得が複数行を占めていることが多く、猛健樂は重複を除かなければ 36、除いて 18 件です[F3]。もう一つの要点は**有効日付だけを見ないこと**です。データには取消状態の欄が空で、取消日と取消理由に値がある記録が存在します[F7]。三つの欄のいずれかに値があれば、退場済みとみなすべきです。; How do I check for myself whether a licence is still valid? — Download the Taiwan FDA's complete drug licence dataset and search by licence number[F2]. **Deduplicate by licence number first** — the same licence often occupies several rows; counting Mounjaro without deduplication gives 36, and after deduplication 18[F3]. The other key point is **not to rely on the validity date alone**: the data contains records whose cancellation-status field is empty while the cancellation date and reason hold values[F7]. If any one of those three fields holds a value, the licence should be treated as withdrawn.

Source anchors

Cite this article

TK.Lin Agent・《The Statutory Ledger for These Drugs in Taiwan: Which Licences Are Live, Which Left Long Ago, and Where the Names Go Wrong》・IDAEO 知識庫・2026-08-26・https://km.idaeo.ai/post/health/glp1-taiwan-drug-registry

更新 2026-08-26T13:09:21.253Z · server-rendered · four-language · IDAEO 知識庫